Patient tolerance to carbonic anhydrase inhibitors

Area of Science:

• Pharmacology
• Ophthalmology
• Nephrology

Background:

• Carbonic anhydrase inhibitors (CAIs) are used to treat various conditions, including glaucoma and epilepsy.
• Understanding the comparative tolerability of different CAIs is crucial for clinical practice.

Purpose of the Study:

• To compare the tolerability of commonly prescribed carbonic anhydrase inhibitors.
• To identify the most and least tolerated agents within this drug class.

Main Methods:

• A crossover study design was employed.
• Participants received acetazolamide tablets, acetazolamide Sequels, dichlorphenamide, ethoxzolamide, methazolamide, and an ascorbic acid placebo.
• Treatment allocation was randomized.

Main Results:

• Acetazolamide Sequels demonstrated the highest tolerability among the evaluated CAIs.
• Methazolamide was the second best-tolerated drug.
• Ethoxzolamide, acetazolamide tablets, and dichlorphenamide were found to be the least tolerated.

Conclusions:

• Acetazolamide Sequels offer a favorable tolerability profile compared to other carbonic anhydrase inhibitors.
• Clinicians should consider patient tolerance when selecting a carbonic anhydrase inhibitor.